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In light of the recent controversies over
the role of animal models for research into
the development of new treatments for
severe malaria, particularly cerebral dis-
ease, a group of scientists came together to
discuss the relative merits of a range of
animal models and their overlap with the
complex clinical syndromes of human
disease. While it was not possible to fully
resolve differences over the utility of the
Plasmodium berghei ANKA model of exper-
imental cerebral malaria, the meeting did
bring the two research communities closer
together to identify further work to
provide information needed to validate
the model and revitalise the development
of other animal models displaying features
of human pathology. The driving force
behind this was the desire to ensure better
translation of experimental findings into
effective treatments for severe malaria.
Introduction
In 2010 there were a number of
publications discussing the relevance of
rodent models for the study of human
cerebral malaria (HCM). These were
prompted by an initial discussion paper
from Professor Nick White and colleagues
(‘‘The murine cerebral malaria phenome-
non’’ [1]) in which the suggestion was
made that the Plasmodium berghei ANKA
(PbA) mouse model of experimental CM
(ECM) did not replicate the pathophysiol-
ogy of cerebral disease in humans, and
which was followed closely by a set of
papers supporting the ECM approach
[2–5]. This has resulted in some polarisa-
tion of the research community on this
topic and an occasionally uncritical appli-
cation of some of the perceived conclu-
sions of this initial paper to other areas of
malaria research using rodent animal
models. This Wellcome Trust–supported
workshopbroughttogetherexperts(Table1)
fromboth sides of the debate and thosewith
expertise related to non-human primate
(NHP) malaria to discuss the clinical
features of severe malaria in humans and
how various animal models might best be
used to advance our knowledge of this
important disease and the development of
therapeutic measures.
What Are the Clinical and
Pathological Features of Severe
Malaria?
An important aspect of falciparum
malaria that has not been always fully
appreciated is the heterogeneity of disease
patterns in humans. Frequently the terms
‘‘severe’’ and ‘‘cerebral’’ when used in
conjunction with the term ‘‘malaria’’ have
been thought to be interchangeable, but
severe malaria is made up of a range of
clinical syndromes, several of which do
not involve coma. Severe malaria shows
both clinical heterogeneity between pa-
tients and the patterns of pathophysiology
observed between adults and children.
Therefore it is important when dealing
with studies on severe malaria that a
reliable and consistent definition of disease
is used. Detailed clinical criteria for the
diagnosis of severe malaria have been
defined by the World Health Organization
[6].
Most studies on severe malaria have
focused on infection by the malaria
parasite Plasmodium falciparum. Adults with
severe malaria show signs of profound
metabolic derangement and cerebral ma-
laria, and may have placental malaria and
(unlike children) multi-organ failure, in-
cluding kidney and liver dysfunction. For
children, severe disease includes metabolic
derangement, cerebral malaria, and severe
malarial anaemia. Frank pulmonary oede-
ma is less common in children. Severe
malaria (particularly lung involvement,
thrombocytopenia, or anaemia, but with-
out coma), although less frequent, can be
caused by Plasmodium vivax [7,8]. Plasmodi-
um knowlesi cases also frequently develop
severe malaria, with limited clinical data
and autopsy findings from a single case
report appearing to show similarities to P.
falciparum pathology but without coma [9].
A principal feature of HCM from nearly
all post-mortem studies is the packing of
sequestered infected erythrocytes (infected
red blood cells [iRBC]) in the brain
microvasculature [10,11], associated with
microvascular obstruction [12]. This may
also be associated with microhaemor-
rhages, although these are also seen in
non-cerebral malaria cases and other
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proportion of brain vessels containing
sequestered iRBC can range from 30%
to 100%, indicating heterogeneity in the
recruitment of iRBC to receptors on the
endothelial cells lining these vessels
[13,14]. The post-mortem studies con-
ducted in Malawi suggested that clinical
diagnosis of fatal HCM in an endemic
area proved false in 25% of cases on
subsequent autopsy, where the cause of
death was due to other diseases [15]. The
need for more precise clinical and patho-
logical definitions of severe cerebral and
non-cerebral malaria is therefore impor-
tant. Direct visualisation of microcircula-
tory obstruction (such as in the retinal
circulation) and associated signs has
helped to provide better specificity in
making a diagnosis [16–20].
Mortality in paediatric HCM occurs
very rapidly, with 50% of deaths being
recorded within 24 hours of admission
and nearly all fatalities by 48 hours. In
adults a similar level of early mortality is
observed, with about 50% of deaths
occurring in the first 48 hours post
admission, but subsequent deaths can take
place later due to other complications such
as renal failure or incidental pneumonia.
Patients with HCM tend to have higher
parasitaemias, and some studies have also
suggested a larger parasite biomass (as
estimated by plasma PfHRP2 levels [21]).
However, infections with hyper-parasitae-
mia without manifestations of HCM also
occur. A key point in interpreting these
findings is the location of the tissue burden
of sequestered parasites in severe disease,
and the immune mechanisms, that atten-
uate disease.
Information on the histological pattern
of severe malaria is still very restricted,
particularly from childhood deaths, in part
due to the difficulty in accessing relevant
human material (see below). Given the
multiple aetiologies of severe disease, this
type of information will be critical in
helping us to understand the relative
contribution of different pathologies to
the clinical signs observed in severe
malaria. A consistent pathological finding
in HCM at autopsy, unique to this disease,
is the presence of sequestered iRBC that
pack brain blood vessels. Indeed, patients
who die soon after admission to a health
care facility may have brain microvas-
cular sequestration as the only significant
pathological feature of CM. However,
observation and correlation of neuropath-
ological features with pre-mortem clinical
diagnosis can be affected by multiple
factors such as time to death, treatment,
and other systemic complications of severe
malarial infection, or may be compro-
mised by misdiagnosis. In this regard there
are some differences between adults and
children, for example, in the degree of
brain swelling and oedema observed using
imaging techniques, and the accumulation
of leukocytes and platelets in cerebral
microvessels, with significant levels seen
in some cases of paediatric HCM but very
few observed in adults, despite clear
evidence (for instance, from circulating
cytokine levels) of a vigorous pro-inflam-
matory host response. Astroglial activation
and blood–brain barrier changes are also
commonly observed in HCM, so inflam-
matory responses elicited within the brain
parenchyma may be more subtle than
merely accumulation of monocytes or
other leukocytes [22,23]. Data are also
available for iRBC sequestration and host
responses in non-brain tissues that repre-
sent other sites for maturation of P.
falciparum within erythrocytes [10].
Adhesion-related pathology in falci-
parum malaria is evident in placental
infections in pregnant women. Here,
placental sequestration of iRBC and the
onset of fetal impairment and disease in
women protected by immunity is linked to
the appearance of a set of parasite variants
expressing a class of PfEMP1 proteins
known as VAR2CSA [24] with atypical
structure and domain composition
[25,26]. A key feature of these parasite
variants is their ability to bind to chon-
droitin sulphate A (CSA) in the placenta
[27], where they are thought to induce
fetal disease through as yet unknown
inflammatory pathways [28].
Important Issues in Research on
Severe Malarial Disease and the
Use of Animal Models
Two key questions, ‘‘what is the path-
ophysiology of severe disease?’’ and ‘‘how
do people living in malaria endemic
regions become protected from severe
disease?’’, cannot be answered fully by
observations of infected humans. While
studies on the clinical definition and
histopathology of HCM and placental
malaria have provided information re-
garding correlates of pathogenesis, the
exact mechanisms whereby malaria para-
sites cause severe disease and how immu-
nity protects against disease despite infec-
tion remain unknown. Parasites with
complex life cycles such as Plasmodium
species have evolved multiple and redun-
dant strategies to deflect and evade the
host immune response, so it is unlikely that
protection will be correlated with the
ability to recognise and neutralise a single
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anti-disease immunity develops relatively
quickly, perhaps after only a few infec-
tions, but this immunity is incomplete, still
allowing lower density blood stage infec-
tion that is accompanied by either mild or
no symptoms [30]. Immunity is also linked
to levels of exposure so that children
appear to acquire anti-disease immunity
at a very early age in areas of high
transmission (and have a distinct pattern
of severe disease, dominated more by
severe malarial anaemia rather than
HCM) [31]. By contrast, malaria naive
adults and older children encountering
the parasite for the first time produce a
different defence response. Linked to
immunity is the question of the role of
inflammation in the pathogenesis of severe
disease. Investigations of this issue require
not only longitudinal clinical studies, but
also the analysis of multiple host responses.
Thus, it is no surprise we do not fully
understand the mechanism of protection
either from severe disease or infection
itself.
Mechanistic studies in animal models
may provide information on the processes
of, and protection from, severe malarial
disease, and there are good examples
where they have provided insights into
features and characteristics of human
malaria infection. Although it is unlikely
that any single model will reproduce the
complexity and spectrum of disease and
immunity observed in human malaria
infections, there are parallels between
some human and animal presentations of
malaria infection (and disease). However,
the choice of the host/parasite combina-
tion is important (see Table S1).
Validity of the Rodent P. berghei
ANKA Model (PbA Mouse Model) for
Human Cerebral Malaria?
In some ways, this is one of the most
challenging questions for the malaria
research community and accordingly
has resulted in a degree of polarisation of
viewpoints. The correct choice of a
combination of experimental animal host
and a malaria parasite able to appropri-
ately mimic the disease pattern seen in
humans is essential. However, it is also
very clear that animal models allow for
more detailed examination of multiple and
specific patholphysiologic processes caused
by malaria infection that is not possible for
clinical studies of human malaria through
the level and scope of experimental
observation and intervention that can be
applied to animals. In discussing the role
of the PbA mouse model of HCM
specifically, the issue that recurred
throughout the meeting concerned the
degree of sequestration of iRBC in the
brains and other organs of P. berghei
ANKA–infected mice. Several groups
provided data that supported the accumu-
lation of iRBC in a number of organs,
sometimes including the brain, and that
higher parasite accumulation was seen in
mice susceptible to ECM. However, the
key piece of information missing was direct
histological evidence of substantial para-
sitised erythrocyte sequestration packing
brain microvessels in a similar pattern to
that observed with HCM.
The consensus of most participants was
that P. berghei ECM, in contrast to HCM,
is associated with marked accumulation of
leukocytes, but not with prominent se-
questration of cytoadherent mature tro-
phozoite/schizont iRBC in brain vessels
[32]. However, a number of participants
emphasised that recent data have provided
evidence of increased iRBC accumulation
during ECM in multiple organs, including
the brain [4]. It was felt that more
research is needed to define this phenotype
of iRBC accumulation during ECM.
ECM is associated with increased accu-
mulation of immune cells in the brain
(particularly monocyte/macrophages and
T cells). In particular, recruitment of
CD8+ T cells to the brain late in disease
pathogenesis, and production of the cyto-
lytic molecules granzyme B and perforin,
is critical for ECM development [33]. In
general, it was agreed that in the absence
of prominent parasitised erythrocyte se-
questration in the brain it is not appropri-
ate to use the PbA mouse model for testing
interventions that may reverse iRBC
adhesion to relieve microvascular obstruc-
tion (a hallmark of HCM). However, since
in both humans and rodents vascular
obstruction, either by iRBC, leukocytes,
or by both, appears to be associated with
features of CM, the PbA mouse model
may be useful to analyse the relationship
between reversal of vessel blockage and
inflammation in CM. The types of endo-
thelial cell microenvironment changes
induced by cytoadherence and inflamma-
tion are not the same [34], although they
share several processes, and as HCM
encompasses more than one pathologic
entity it is possible that disease may be
caused by different vascular conditions.
Thus, there is room for investigating these
different mechanisms in relation to human
disease. For HCM, both post-mortem and
in vitro evidence show that cytoadherence
of iRBC to brain endothelium has specific
functional effects [35–37].
ECM is clearly an inflammatory syn-
drome with local vascular endothelial
activation with inflammatory cytokines
playing an essential role, which has
obvious differences and some similarities
to the clinical and pathological features of
HCM, for example, the signs of vascular
inflammation/damage seen in some cases
of paediatric HCM [15]. Some studies
have suggested associations between high
levels of cytokines and severe malaria
[38,39], but these have been challenged
recently by work showing that high levels
of pro-inflammatory cytokines such as
tumor necrosis factor (TNF) are poor
indicators of HCM in African children
and that markers of localised endothelial
cell inflammation (e.g., Angiopoietin 1/
Angiopoietin 2 ratio) are more strongly
associated [40,41]. It is possible that
inflammatory processes play an essential
role in a subset of clinical patients.
Therefore, (mechanistic) studies of ECM
in PbA mouse models may provide
insights into inflammatory processes and/
or immune responses and their role in
HCM pathology. An alternate view,
strongly articulated at the meeting, was
that ECM in the PbA mouse model was
so very different to HCM that the
pathological and therapeutic interpreta-
tions derived from it were largely irrele-
vant for the understanding and treatment
of HCM. It was suggested that future
experimental studies in the mouse and
other animal models (i.e., NHPs) would
be better directed towards pathological
processes that could be shown to be
similar in human infection and the animal
models. Other features of ECM, such as
PbA-iRBC adhesion to CD36, may have
relevance to HCM. Although CD36 is
expressed at very low levels on cerebral
endothelial cells in the human and mouse,
it is abundantly expressed on platelets,
macrophages (cells that accumulate in the
brain in ECM), on endothelium in other
vascular compartments, and is also pres-
ent on microparticles. The role of plate-
lets and microparticles in human malaria
has become a major topic of research
[42,43] and may become more relevant to
identifying potential interventions for
HCM.
One of the benefits of the discussion
about ECM studies at the meeting was a
clarification of how inhibitor or interven-
tion studies of adjuvant treatments in
mice should be interpreted. In most
studies, the inhibitors/drugs are given
before the development of neurological
symptoms, thereby providing information
on disease processes in ECM but not
necessarily on the identification of viable
therapies. The validity of carrying out
human clinical trials, often in underpow-
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type of rodent malaria data is question-
able. On the other hand, human trials
carried out on the basis of pathophysiol-
ogy studies in humans (e.g., anti-TNF
[44]; anti-convulsion therapy [45]; fluid
management [46]) have not been partic-
ularly good at reducing morbidity or
mortality either, so the lack of progress
in this area may reflect our lack of
knowledge and the complexity of HCM.
Another benefit of the reappraisal of
ECM at the workshop was the recogni-
tion of the diversity of phenotypes avail-
able with rodent model systems through
the use of different protocols and P. berghei
isolates/strains. For example, the level of
ECM induced by P. berghei infections (i.e.,
the percentage of mice showing ECM
pathology) is influenced by (small) differ-
ences between isolates/strains and cloned
laboratory lines (i.e., NK65, K173, and
ANKA [47]), host diet [48–50], starting
dose of infection, etc. Parasites of strains
such as NK65 and (cloned) lines of other
strains that have a stronger preference for
invading reticulocytes appear to have a
lower capacity to induce ECM. There-
fore, standardisation of protocols for
maintaining and generating the genetic
characterisation of parent parasite lines is
essential, as is the analysis of multiple
infection parameters in studies that ana-
lyse interventions aimed at reducing
ECM.
What Other Rodent Models of
Human Cerebral Malaria Are
Available or Possible?
With questions raised about the rele-
vance of the PbA mouse model for HCM,
a consideration of alternative rodent
models was undertaken. Improvements
based on genetic manipulations to the
mouse model were discussed, such as a
humanised rodent system. Schizonts of P.
berghei sequester and express parasite
ligands on the surface membrane of iRBC
[51]. The characterisation and the genetic
modification of P. berghei ligands involved
in binding to host receptors might offer
novel possibilities in the development of
small-animal models for analysing the
sequestration properties of P. falciparum
ligands that have hitherto only been
examined in vitro. This could be per-
formed by, for example, substituting P.
berghei ligands with PfEMP-1 proteins or
domains. Using in vivo imaging in con-
junction with such ‘‘falciparumised’’ P.
berghei parasites in mice expressing human
receptors (e.g., human ICAM-1) may
create an in vivo screening system for
testing inhibitors that block P. falciparum
cytoadherence. While this ‘‘double trans-
genic’’ model is not available yet, human
graft systems have been investigated using
SCID mice, as transient models allowing
perfusion of P. falciparum iRBC in human
dermal tissue in a format where detailed
microscopy is facilitated [52], and in
investigating the role of Fc receptors in
malaria [53]. The graft model allows
detailed examination of the interaction
between parasites and the host in a three-
dimensional tissue, rather than the two-
dimensional ex-vivo models commonly
used. Complex humanised models for
longer-term experiments on P. falciparum
infections in NOD/SCID mice have also
been described [54]. Results suggest that
these do not show cytoadherence [55] or
ECM, and so they cannot be used for
HCM research. Uptake of graft models
has been extremely limited and further
work is needed to validate their potential
use and to develop the protocols to extend
the range of tissues available.
Non-Human Primate Models for
HCM or Severe Malarial Disease
Given the greater genetic relatedness of
primate hosts and primate parasites, the
importance of NHP and malaria parasite
combinations as appropriate systems for
researchers to study ECM was also
discussed at the workshop. Further, it
was noted that a degree of reluctance to
use NHP models in malaria research has
led to a reduction in the resources needed
to support such research. If NHP systems
are capable of providing models of HCM
and other types of severe disease in human
malaria, then significant investment will be
required to grow and sustain this research
community, train young researchers, and
provide the resources for wider participa-
tion of clinical and laboratory oriented
investigators.
Several host/parasite combinations
were discussed (Table 1): Plasmodium coat-
neyi is a simian parasite that in Japanese
(Macaca fuscata) and rhesus (Macaca mulatta)
macaques exhibits phenotypic characters
that mimic P. falciparum iRBC sequestra-
tion, rosetting, and clinically severe disease
[56–60]; similarly, Plasmodium fragile iRBC
profoundly sequester by cytoadhesion in
the vasculature of various tissues and
organs and produce severe disease in
rhesus monkeys [61,62]. These two ma-
laria parasite species, like P. knowlesi, but
not P. berghei and other rodent malarias,
have var-like gene families that exhibit
antigenic variation and adhesion proper-
ties [63–65]. In contrast to the PbA mouse
model, the presence of cerebral microvas-
cular iRBC sequestration through cytoad-
hesion in cerebral blood vessels is proven
for these two macaque monkeys, and they
therefore offer an alternative for examin-
ing the association of parasite-specific
adhesive events in the brain with disease
and underlying pathogenic mechanism(s).
These models also offer the potential to
use more sophisticated approaches for
neuroimaging, such as functional MRI
[66], which has been applied to HCM
[67,68] and in initial studies of P. coatneyi
malaria [69].
P. knowlesi infections in M. mulatta
produce ‘‘severe disease’’ that is almost
always lethal to this host. Mature P.
knowlesi iRBC in rhesus monkeys partially
sequester in a variety of tissue sites via the
variant-antigen products of the large var-
like SICAvar multi-gene family [64,65].
Although it is clear that severe disease in
the P. knowlesi rhesus macaque model can
mimic some clinical syndromes of P.
falciparum severe disease in humans, it is
questionable whether it is a useful model
for HCM, as neither adhesion of iRBC to
cerebral vessels or clinical signs of HCM
have been noted. Although it is unclear if
P. knowlesi in rhesus monkeys is a satisfac-
tory model for HCM, from initial reports
it is certain to be a model for human
severe disease caused by this parasite
[9,70,71]. P. knowlesi in the olive baboon
(Paplio anubis) [72] has been suggested as
an HCM model because of apparent
cerebral iRBC sequestration and neuro-
logical signs in terminal infections, but this
needs further investigation. P. falciparum
will also infect and cause severe disease
(anaemia, acute nephritis, cardiopathy,
metabolic collapse) and death in neotrop-
ical monkeys such as various species of
Aotus (owl monkeys).
There are, however, limitations to this
primate model since symptoms of CM and
cerebral vascular sequestration have not
been noted in New World monkeys
infected with P. falciparum.
What Models Are Available for Other
Aspects of Malaria Research?
At the meeting, brief mention was made
of models for placental malaria, acute
respiratory distress (ARDS), anaemia, and
immunity. The lack of the var multi-gene
family in rodent and some primate malaria
species (i.e., Plasmodium cynomolgi, which is a
model for P. vivax) means that the roles of
the encoded variant antigens in placental
sequestration cannot be investigated.
However, NHP models such as P. coatneyi
in rhesus monkeys [73] or P. falciparum in
Aotus monkeys are also available; and P.
coatneyi expresses the comparable variant
antigen multi-gene family (J. Barnwell and
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more, analysis of the effects of inflamma-
tory responses and parasite accumulation/
sequestration in the placenta and foetus
may provide insights into the role of pro-
inflammatory cytokines in malarial pla-
cental pathology [74–77]. Major limita-
tions of many mouse models are the lack
of a natural chronic infection, with the
exception of Plasmodium chabaudi, and the
ability of some host/parasite systems to
develop almost complete immunity after a
single infection. Investigation of the effects
of malaria on multiple pregnancies is
therefore not possible in most rodent
models except in drug-induced chronic P.
berghei infection in mice, which is one of
the best described models for rodent
placental malaria. A ‘‘humanised’’ PbA
mouse model may also be developed for
analysing sequestration properties dur-
ing pregnancy. Transgenic P. berghei
parasites may be generated that express
Pf VAR2CSA or CSA binding domains
on the surface of iRBC. Such parasites
in combination with a ‘‘humanised
placental malaria mouse model’’ may
offer a screening system for in vivo
testing inhibitors (small molecule inhib-
itors, antibodies) that block P. falciparum
sequestration.
Several recent studies indicate that P.
berghei in mice can be models to investigate
malaria-associated lung pathology [78–
81]. For these models it was felt that, as
with CM, detailed comparisons between
lung pathology in the rodent models and
lung pathology in humans are required to
validate their use for developing thera-
pies/interventions.
Models for anaemia were also consid-
ered to be important to support human
clinical studies. P. chabaudi [82] and P. yoelii
17xNL in mice and P. berghei in Brown
Norway rats (C. Janse and B. Franke-
Fayard, unpublished data) were briefly
mentioned as possible models for malarial
anaemia. However, the lack of a real
chronic infection and the rapid acquisition
of sterilising immunity preclude the use of
many rodent models to study anaemia in
chronic infection, which would be more
reflective of severe malaria in children.
However, mechanisms of disruption of
bone marrow haematopoeisis [83] and
dyserythropoeisis in acute infection can be
readily investigated.
Based on mainly unpublished reports,
several NHP models offer opportunities
for studying severe anaemia in both acute
and chronic infection in regards to clari-
fying the mechanisms and interventions
for clearance dynamics of uninfected
RBC, bone marrow differentiation, and
dyserythropoesis in severe malarial anae-
mia. Simian malarias such as P. coatneyi in
acute infections produce profound anae-
mia that is life-threatening due to clear-
ance of uninfected erythrocytes and a
dyserythropoesis that does not allow a
compensatory reticulocytosis (A. Moreno
and M. Galinski, unpublished data), as
well as severe anaemia later on during
chronic severely recrudescing infections
that can last for months or over a year
(W. Collins, unpublished data). P. cyno-
molgi, like P. vivax, also produces a
profound anaemia during acute infections
(A. Moreno and M. Galinski, unpublished
data). Severe lethal anaemia also develops
in semi-immune neotropical primates with
P. falciparum infections going into chronic
infection and upon reinfection or chal-
lenge of animals induced into a semi-
immune state (J. Barnwell and W. Collins,
unpublished data). P. vivax infections in
neotropical monkeys also develop severe
anaemia during acute and chronic infec-
tions [84,85].
It was generally agreed that rodent
models can provide relevant information
on mechanisms of host defence and
immunity to all stages of the infection. A
recent example of this is the demonstra-
tion of suppression of liver stage malaria
parasite development in the presence of a
blood stage infection [86]. P. chabaudi and
P. yoelii in mice and P. berghei in Brown
Norway rats show self-resolving infections
with low peak parasitaemias and anaemia.
It is generally assumed that immunity in
humans and NHPs develops slowly over
many months and incompletely, in con-
trast to rodents where immunity develops
rapidly and is frequently sterilising. Only
P. chabaudi in mice [87] and P. berghei in
rats exhibit low density chronic infections
for prolonged periods (2–3 months),
whereas in humans and NHPs single
infections may last years and decades.
One feature in common to human, NHP,
and rodent infections is that protective
immune responses are generally species-,
genotype-, and variant-specific, although
in the case of variant-specific immunity
some of the antigens that are products of
multi-gene families (e.g., PfEMP1 and
PIR) exhibit evolutionarily distinct se-
quences and characteristics in the species
and strains where they exist. Humans are
generally exposed to different strains,
genotypes, and variants of the parasite,
whereas in most experimental model
studies the same cloned parasite line or a
single strain/isolate is used for repeated
infections. It was emphasised that when
humans are similarly re-exposed to the
same strain/genotype, acquisition of im-
munity is generally similar to that of mice.
A recommendation therefore was that
studies on immunity to re-infection and
the effectiveness of immunological memory
should be carried out in mice or monkeys
using different strains of the same parasite
species. More immunological studies in
mouse/rat peripheral blood, for compari-
son with humans, would also be valuable.
Another important point of experimental
model studies was that direct injection of
infected erythrocytes to initiate infections
wasnormalpracticeinthe studyofimmune
mechanisms and immunopathology. How-
ever, this does not reproduce the sequence
of the natural infection where infection
starts with a mosquito bite and inoculation
of sporozoites. It was discussed here that
blood stage infections of some Plasmodium
species may look very different and be
considerably less virulent when initiated via
the natural route compared with injection
of iRBC. This should be taken into account
when translating findings from animal
models to humans.
At the meeting the use of animal
models for development and testing of
vaccines and drugs was only briefly
mentioned. Discussion of this area was
outside the scope of the meeting, but it
was acknowledged that animal models
have played a major role in the develop-
ment of anti-malarial therapies, including
those targeting different stages in the
parasite life cycle [2].
Conclusions and
Recommendations
There was universal support for
stronger interactions between
groups working on human and
animal studies, both to improve
current models and to promote
more realistic translation of labora-
tory findings into clinical studies.
The importance of animal models in
malaria research was recognised by all
participants. However, it was not possible
to reach a consensus on the role of the
PbA mouse model for studies on HCM.
The basis of the disagreement centred on
the relative importance of iRBC adhesion
to brain endothelial cells in causing HCM
pathology. There is evidence to support
the presence of PbA iRBC in cerebral
vessels in ECM, but this accumulation
represents a minor (if any) concentration
of iRBC compared to the peripheral
parasitaemia, unlike the levels of adherent
iRBC seen with P. falciparum. In the
absence in the PbA mouse ECM model
of this hallmark of human CM, and based
on observations of pathologic changes to
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iRBC, it was the view of some of the
participants that the mouse/PbA system
was not a useful model of HCM.
However, it was pointed out that we do
not know that P. falciparum cytoadherence
causes HCM and its role in pathology
may have been exaggerated. At the same
time, comparisons of ECM and HCM
have revealed many similarities (although
the extent of these was also contentious),
and therefore the PbA mouse model can
provide a platform for detailed mechanis-
tic experiments in this field. Thus, the
overriding conclusion of this meeting was
that there are presently genuine differ-
ences of opinion on this topic, but this was
coupled with the genuine willingness
indicated by all parties at the meeting to
try overcoming these differences by col-
laborating. Specifically, these centered
around two major areas: 1) A more
careful use of the term ‘‘drug’’ when
applied to interventions used in ECM,
particularly when these were applied
prior to the physiological signs of cerebral
disease in mice, although the validity of
the use of inhibitors to understand
pathological processes was appreciated.
2) A bi-directional exchange of resources
and knowledge to provide better infor-
mation about the complex pattern of
human disease to scientists using animal
models and better access for this latter
community to human tissues in order to
validate findings obtained from model
systems. The major issues raised at the
meeting are summarised in Box 1.
The main recommendations from
the meeting were:
(i) Coordinated pathological stud-
ies across species
As with many disciplines, one of the
major confounders of research is the lack
of standardisation. This is particularly
clear with the mouse/PbA model, where
differences between parasite lines and
environmental factors, such as host diet,
can influence features of pathology. Thus,
there was a general consensus that tissue
specimens from animal models of CM
produced in different laboratories need to
be analysed using uniform methods of
histology and quantification. While it was
questioned whether the mouse/PbA mod-
el is appropriate to derive cytoadhesion-
based therapies for CM, it does not
preclude this model as a vehicle to
investigate possible inflammatory process-
es in severe disease, including CM.
Further research is needed to link animal
and human studies to allow a comparison
of the pathology of disease across a
spectrum of clinical syndromes and there-
by to develop the much needed animal
models that can drive research into the
development of interventions for severe
malaria. The mouse model may be useful
in studying tissues where inflammation is
known to play a significant role in human
pathology, such as the lung. But in some
clinically important syndromes of human
malaria such as malaria-associated acute
renal failure in adults, very little data are
available on the clinical or pathological
correlates in animal models. However,
NHP infections in rhesus monkeys involv-
ing several simian malaria species can
cause acute renal failure.
(ii) More use of primates and
better access to primates
Strengths of studies on NHPs are that
their physiology and acquisition of immu-
nity to infection are more similar to
humans than mice, and their size may
also permit a wider range of studies. Also,
within limits, neotropical (New World)
primates can be infected with human
P. falciparum and P. vivax (as well as P.
knowlesi). Infections with P. fragile, P. coat-
neyi, and P. knowlesi in certain macaque
species are potential models of CM,
anaemia, placental malaria, and ARDS
and other severe malaria syndromes in
humans [88]. NHP models can also
facilitate studies of malaria parasite
multi-species co-infections and co-morbid-
ities, e.g., affect of worm infections on the
severity of malaria, and overlapping syn-
dromes, e.g., metabolic acidosis, anaemia,
etc. One drawback is that the currently
available NHP models, such as P. coatneyi
in Japanese or rhesus macaques, exhibit
cerebral sequestration but it is not clear
how similar they are to HCM.
NHP models of vaccine efficacy (using
GMP material) have been reasonably
predictive of human clinical trials (albeit
mainly negative, as are most clinical trials).
Unlike rodent models, they do provide
access to some of the life cycle stages that
are not available in vitro, including
hypnozoites.
NHP studies for malaria research re-
quire specialised scientific centres with the
regulatory framework, access to NHP
animals, and expertise to conduct such
research. The group recognised that
investment in existing NHP research
centres would be a valuable and cost-
effective way forward, coupled with a
scheme to provide ‘‘placements’’ for sci-
entists from collaborating laboratories.
This would ensure an enhanced and
vibrant scientific environment for malaria
research within the NHP centres and
disseminate the potential for NHP re-
search to the community.
(iii) Clear discrimination between
interventionand mechanistic studies
One of the more fundamental prob-
lems of animal models highlighted by
recent publications has been the confu-
sion between studies aimed at collecting
mechanistic information on disease pro-
cesses and studies aimed at screening for
potential therapies against severe disease,
perhaps most graphically demonstrated
by the figures of 38 of 42 interventions for
ECM working but none of 16 being
successful in HCM. The limitations asso-
ciated with the application of therapies
before clinical signs, often used in PbA
mouse model studies, need to be recog-
nised. Relevant animal models are highly
desirable, as studies of humans with
severe malaria are by definition limited
to situations where clinical interventions
are the priority. Thus, interpretations of
the result of therapies preventing CM
must be done in the context of anti-
malarial drug treatment and other sup-
portive measures.
(iv) Facilities to support research
on severe malaria
One of the major outcomes of the
workshop was the requirement for further
development of facilities for research.
Box 1. Major Issues from the Meeting
N The mouse and human malaria research communities need to work together
more closely to support better translation of laboratory studies into clinical
leads.
N It was not possible to resolve the disagreements over the use of the P. berghei
ANKA mouse model for human cerebral malaria, particularly in the area of
cytoadherence-associated pathology. It was agreed that researchers using the
P. berghei model should be cautious in their interpretation of inhibitor studies,
particularly where the intervention is given prior to symptoms.
N The spectrum of malarial disease in humans is broad and we do not fully
understand the pathological mechanisms.
N Development and standardisation of animal models, including renewed
investment in non-human primate systems, is a priority.
PLoS Pathogens | www.plospathogens.org 6 February 2012 | Volume 8 | Issue 2 | e1002401We need to understand more about
human disease and immunity and com-
municate more effectively with research-
ers working on animal studies so that we
can identify appropriate models for
detailed mechanistic studies. Apart from
a general need for more work in this
area, two specific areas were identified
for further development:
(v) Tissue biobanking
Our lack of knowledge of the detailed
pathology of human disease is part of the
problem in identifying relevant animal
models. To address this, the creation of a
tissue biobank was proposed. This re-
source would make material from hu-
mans with malaria available to the
broader research community so that
validation of initial observations from
well-characterised clinical specimens
c o u l db ee x a m i n e df r o mav a r i e t yo f
perspectives using novel technologies.
There are clearly ethical and logistic
issues associated with this, but the
benefit accrued in terms of validating
animal studies by having good access to
human tissues was deemed to outweigh
the effort that would be required to set
this up properly. The use of tissue
microarrays, where multiple cases can
be examined on a single slide, may
facilitate this approach.
(vi) Standardisation of animal
models
It was proposed that a repository of
standard parasite lines and protocols
relating to the maintenance/passage of
parasite lines and their hosts should be
created. There should also be an oppor-
tunity for members of the research com-
munity to share information (particularly
unpublished data that is not widely
available), including data such as a com-
parison of parasite sequences.
Supporting Information
Table S1 Animal host/malaria parasite
combinations for the study of human
malaria pathogenesis.
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